Skip to main content
. Author manuscript; available in PMC: 2014 May 29.
Published in final edited form as: Breast Cancer Res Treat. 2011 Apr 9;131(3):849–858. doi: 10.1007/s10549-011-1500-8

Figure 4. Over-expression of KIFC3 and KIF5A does not mediate resistance to doxorubicin or vincristine in breast cancer cells.

Figure 4

A & B, MDA MB231 cells. C & D, MDA MB468 cells. Cells infected with retroviral vectors encoding KIFC3 or KIF5A or with empty vector controls were treated with doxorubicin (Dox) or vincristine (Vin) for 24 hours. After 5–6 days, the cells were lysed and the A260 was measured. The percentages of surviving cells were calculated relative to untreated controls. The data represent means ± SD of two experiments in which each measurement was performed in triplicate. We chose the highest ranked KIFs from the MDACC data set of pre-treatment cancer for this in vitro experiment, given that the specific treatment regimen for the data set included taxanes and anthracyclines.